Kubota Vision Inc. is teaming up with two companies to develop, manufacture, supply, and sell its eyeMO ophthalmic self-monitoring OCT device.

久保田视觉公司正与两家公司合作，开发、制造、供应和销售其eyeMO眼科自我监测OCT设备。

The Japanese firm has executed an agreement (a letter of intent, actually) with AUROLAB (Madurai, India) and another with IQVIA. The AUROLAB deal provides the Indian company with an exclusive license to develop, manufacture, and distribute eyeMO in its core markets—ndia, Pakistan, Afghanistan, Bangladesh, Bhutan, Maldives, Nepal, and Sri Lanka, as well as select underserved markets in Asia, Africa, Latin America, and the Middle East.

这家日本公司与AUROLAB（印度马杜赖）和IQVIA分别签署了一份协议（实际上是一份意向书）。AUROLAB协议为这家印度公司提供了在其核心市场新德里亚、巴基斯坦、阿富汗、孟加拉国、不丹、马尔代夫、尼泊尔和斯里兰卡以及亚洲、非洲、拉丁美洲和中东部分服务不足的市场开发、制造和分销eyeMO的独家许可。

“We are happy to align with Kubota Vision in making the portable OCT a much-needed device for low-resource settings, especially when patients’ access to eye clinics is challenging,” AUROLAB Managing Director R.D. Sriram stated. .

AUROLAB董事总经理R.D.Sriram表示：“我们很高兴与Kubota愿景保持一致，使便携式OCT成为低资源环境下急需的设备，尤其是当患者进入眼科诊所面临挑战时。”。。。

AUROLAB manufactures a wide range of ophthalmic consumables such as intraocular lenses, surgical sutures, pharmaceutical products, surgical blades, and equipment. It is the manufacturing facility of Aravind Eye Care Hospital (AECS), and performs more than 4.5 million surgeries and treatments annually—one of the world's highest numbers of annual surgeries.

AUROLAB生产各种眼科耗材，如人工晶状体、手术缝线、药品、手术刀片和设备。它是Aravind眼科医院（AECS）的生产设施，每年进行450多万次手术和治疗，是世界上年度手术数量最多的医院之一。

It offers numerous services, including eye exams, surgeries, and rehabilitation services. .

它提供多种服务，包括眼科检查、手术和康复服务。。。

“We are excited to accelerate our goal of bringing eyeMO to people in need around the world by partnering with AUROLAB, part of the Aravind Hospital Group. Aravind Hospital Group is the world's largest eye hospital, performing 450,000 eye surgeries annually and distributing eye care equipment in over 160 countries worldwide,' Kubota Vision Chairman, President, and CEO Ryo Kubota, M.D., Ph.D., said. 'We believe that combining performance with cost-effectiveness is an important factor in promoting eyeMO in the global market.

“我们很高兴与Aravind Hospital Group旗下的AUROLAB合作，加快实现将eyeMO带给世界各地有需要的人的目标。Aravind Hospital Group是世界上最大的眼科医院，每年进行45万次眼科手术，并在全球160多个国家分发眼科护理设备，”久保田视觉董事长、总裁兼首席执行官Ryo Kubota医学博士援助。“我们认为，将性能与成本效益相结合是在全球市场推广eyeMO的一个重要因素。

We will continue to develop and expand the applications of eyeMO to alert patients and their physicians of disease progression and re-treatment needs by facilitating at-home and in-office use in countries and regions where medical care is limited.” .

我们将继续开发和扩大eyeMO的应用，通过在医疗保健有限的国家和地区促进家庭和办公室使用，提醒患者及其医生疾病进展和再治疗需求。”。。

Kubota Vision's vendor agreement with IQVIA Services Japan G.K. obliges the latter firm to manage a clinical study funded by Chugai Pharmaceutical Co. Ltd., and pay for eyeMO's loan to Chugai. The study will verify whether the device can be used in patients with diabetic macular edema in their homes, and the validity of retinal thickness measurements and retinal status measurements for determining the presence of intra- and subretinal edema will occur.

久保田视觉与IQVIA Services Japan G.K.签订的供应商协议要求后者管理由Chugai Pharmaceutical Co.Ltd.资助的临床研究，并支付eyeMO向Chugai的贷款。该研究将验证该设备是否可用于家中糖尿病黄斑水肿患者，以及视网膜厚度测量和视网膜状态测量用于确定视网膜内和视网膜下水肿存在的有效性。

A feasibility analysis will be conducted prior to this study. .

本研究之前将进行可行性分析。。。

“eyeMO is a retinal monitoring device that aims to improve patient prognosis through promotion of home care in the field of ophthalmology. We are very pleased to have the opportunity to validate this device in this study and to see our technology being used even more extensively,” Kubota said.

库博塔说：“eyeMO是一种视网膜监测设备，旨在通过在眼科领域推广家庭护理来改善患者预后。我们很高兴有机会在本研究中验证该设备，并看到我们的技术得到更广泛的应用。”。

eyeMO (Patient Based Ophthalmology Suite) is a portable, low-cost, home-based, remote and in-office ophthalmic OCT1 device for monitoring of retinal diseases remotely or in an office setting. The small handheld device addresses needs in mobile Health (mHealth2) applications for self-monitoring of retina health by patients in the home and in remote field locations.

eyeMO（基于患者的眼科套件）是一种便携式，低成本，基于家庭，远程和办公室的眼科OCT1设备，用于远程或在办公室环境中监测视网膜疾病。这种小型手持设备满足了移动健康（mHealth2）应用的需求，可用于家庭和偏远地区患者对视网膜健康的自我监测。

eyeMO aims to improve ophthalmic treatment outcomes in patients diagnosed with and treated for wet age-related macular degeneration, diabetic macular edema, and other neovascular retinal diseases. eyeMO is being designed to detect nascent disease progression and support patient re-treatment prior to irreversible vision loss due to disease progression.

eyeMO旨在改善被诊断和治疗湿性年龄相关性黄斑变性，糖尿病性黄斑水肿和其他新生血管性视网膜疾病的患者的眼科治疗效果。eyeMO旨在检测新生疾病进展，并在疾病进展导致不可逆转的视力丧失之前支持患者重新治疗。

Key features are low cost and a patient-friendly design to be used directly by patients at home. eyeMO is being designed to capture changes in retinal anatomy. Network connectivity and cloud-based technologies are used to alert the patients and their physicians of disease progression and re-treatment needs. .

主要特点是低成本和方便患者的设计，可供患者在家中直接使用。eyeMO旨在捕捉视网膜解剖结构的变化。网络连接和基于云的技术用于提醒患者及其医生疾病进展和再治疗需求。。。

Kubota Vision Inc. is a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co. Ltd., committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for patients. Kubota Pharmaceutical group’s pipeline includes a wearable device for myopia control using Kubota Glass technology and a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients..

久保田视觉公司是久保田制药控股有限公司的全资子公司，致力于将创新转化为多样化的药物和设备组合，以保护和恢复患者的视力。久保田制药集团的管道包括使用久保田玻璃技术控制近视的可穿戴设备和用于监测新生血管性视网膜疾病的手持式OCT设备，供患者直接使用。。

References

参考文献

1 Optical Coherence Tomography (OCT) is a non-invasive tool that uses light waves to take cross-section pictures of the retina.

1光学相干断层扫描（OCT）是一种非侵入性工具，它使用光波拍摄视网膜的横截面照片。

2 mHealth refers to the usage of mobile communications technology and devices to enhance access to healthcare information, improve distribution of routine and emergency health services, and provide diagnostic services.

2 mHealth是指使用移动通信技术和设备来增强对医疗保健信息的访问，改善常规和紧急医疗服务的分布，并提供诊断服务。